Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Dec;64(6):1019–1024. doi: 10.1038/bjc.1991.457

Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse.

Y Iino 1, D M Wolf 1, S M Langan-Fahey 1, D A Johnson 1, M Ricchio 1, M E Thompson 1, V C Jordan 1
PMCID: PMC1977873  PMID: 1764361

Abstract

We investigated the ability of high concentrations of oestradiol to reverse the growth inhibitory action of tamoxifen on MCF-7 breast cancer cells in vivo. Tamoxifen inhibits the oestradiol stimulated growth of MCF-7 cells in athymic mice. Using a sustained release preparation of tamoxifen we consistently achieved serum concentrations of the drug in the 40 to 50 ng ml-1 range and much higher levels in tissues. These serum levels are sufficient to inhibit the oestrogen stimulated growth of MCF-7 tumours exposed to physiologic (i.e. 300-600 pg ml-1 serum oestradiol concentrations). However, by administering dosages that increase serum oestradiol concentrations to 900-2000 pg ml-1, mimicking the increase often observed clinically in premenopausal women taking tamoxifen, we show that the growth inhibitory action of tamoxifen can be partially reversed. Serum tamoxifen levels were elevated to nearly 400 ng ml-1 by injecting 1 mg day-1 tamoxifen (IP 3 x weekly); this dosage was more effective at inhibiting oestradiol stimulated tumour growth than subcutaneous tamoxifen capsules alone. Our data suggest that at low serum levels tamoxifen may not act optimally. There may be a need to monitor tamoxifen levels in premenopausal patients to ensure that they are high enough not to be overcome by a tamoxifen induced increase in ovarian steroidogenesis.

Full text

PDF
1019

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adam H. K., Douglas E. J., Kemp J. V. The metabolism of tamoxifen in human. Biochem Pharmacol. 1979;28(1):145–147. doi: 10.1016/0006-2952(79)90283-1. [DOI] [PubMed] [Google Scholar]
  2. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet. 1987 Jul 25;2(8552):171–175. [PubMed] [Google Scholar]
  3. Buchanan R. B., Blamey R. W., Durrant K. R., Howell A., Paterson A. G., Preece P. E., Smith D. C., Williams C. J., Wilson R. G. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol. 1986 Sep;4(9):1326–1330. doi: 10.1200/JCO.1986.4.9.1326. [DOI] [PubMed] [Google Scholar]
  4. Campen C. A., Jordan V. C., Gorski J. Opposing biological actions of antiestrogens in vitro and in vivo: induction of progesterone receptor in the rat and mouse uterus. Endocrinology. 1985 Jun;116(6):2327–2336. doi: 10.1210/endo-116-6-2327. [DOI] [PubMed] [Google Scholar]
  5. Cole M. P., Jones C. T., Todd I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971 Jun;25(2):270–275. doi: 10.1038/bjc.1971.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fisher B., Costantino J., Redmond C., Poisson R., Bowman D., Couture J., Dimitrov N. V., Wolmark N., Wickerham D. L., Fisher E. R. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989 Feb 23;320(8):479–484. doi: 10.1056/NEJM198902233200802. [DOI] [PubMed] [Google Scholar]
  7. Gottardis M. M., Robinson S. P., Jordan V. C. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem. 1988;30(1-6):311–314. doi: 10.1016/0022-4731(88)90113-6. [DOI] [PubMed] [Google Scholar]
  8. Groom G. V., Griffiths K. Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol. 1976 Sep;70(3):421–428. doi: 10.1677/joe.0.0700421. [DOI] [PubMed] [Google Scholar]
  9. Horwitz K. B., Koseki Y., McGuire W. L. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology. 1978 Nov;103(5):1742–1751. doi: 10.1210/endo-103-5-1742. [DOI] [PubMed] [Google Scholar]
  10. Ingle J. N., Krook J. E., Green S. J., Kubista T. P., Everson L. K., Ahmann D. L., Chang M. N., Bisel H. F., Windschitl H. E., Twito D. I. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol. 1986 Feb;4(2):178–185. doi: 10.1200/JCO.1986.4.2.178. [DOI] [PubMed] [Google Scholar]
  11. Jordan V. C., Collins M. M., Rowsby L., Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol. 1977 Nov;75(2):305–316. doi: 10.1677/joe.0.0750305. [DOI] [PubMed] [Google Scholar]
  12. Jordan V. C., Fritz N. F., Tormey D. C. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res. 1987 Jan 15;47(2):624–630. [PubMed] [Google Scholar]
  13. Jordan V. C., Lababidi M. K., Mirecki D. M. Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice. Eur J Cancer. 1990;26(6):718–721. doi: 10.1016/0277-5379(90)90125-d. [DOI] [PubMed] [Google Scholar]
  14. Langan-Fahey S. M., Tormey D. C., Jordan V. C. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer. 1990;26(8):883–888. doi: 10.1016/0277-5379(90)90191-u. [DOI] [PubMed] [Google Scholar]
  15. Manni A., Pearson O. H. Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep. 1980 Jun-Jul;64(6-7):779–785. [PubMed] [Google Scholar]
  16. Manni A., Trujillo J. E., Marshall J. S., Brodkey J., Pearson O. H. Antihormone treatment of stage IV breast cancer. Cancer. 1979 Feb;43(2):444–450. doi: 10.1002/1097-0142(197902)43:2<444::aid-cncr2820430207>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  17. Murphy L. C., Sutherland R. L. A high-affinity binding site for the antioestrogens, tamoxifen and CI 628, in immature rat uterine cytosol which is distinct from the oestrogen receptor. J Endocrinol. 1981 Oct;91(1):155–161. doi: 10.1677/joe.0.0910155. [DOI] [PubMed] [Google Scholar]
  18. Powles T. J., Tillyer C. R., Jones A. L., Ashley S. E., Treleaven J., Davey J. B., McKinna J. A. Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme. Eur J Cancer. 1990;26(6):680–684. doi: 10.1016/0277-5379(90)90116-b. [DOI] [PubMed] [Google Scholar]
  19. Robertson J. F., Walker K. J., Nicholson R. I., Blamey R. W. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer. Br J Surg. 1989 Dec;76(12):1262–1265. doi: 10.1002/bjs.1800761213. [DOI] [PubMed] [Google Scholar]
  20. Robinson S. P., Jordan V. C. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res. 1989 Apr 1;49(7):1758–1762. [PubMed] [Google Scholar]
  21. Robinson S. P., Langan-Fahey S. M., Johnson D. A., Jordan V. C. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos. 1991 Jan-Feb;19(1):36–43. [PubMed] [Google Scholar]
  22. Sawka C. A., Pritchard K. I., Paterson A. H., Sutherland D. J., Thomson D. B., Shelley W. E., Myers R. E., Mobbs B. G., Malkin A., Meakin J. W. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res. 1986 Jun;46(6):3152–3156. [PubMed] [Google Scholar]
  23. Sherman B. M., Chapler F. K., Crickard K., Wycoff D. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest. 1979 Aug;64(2):398–404. doi: 10.1172/JCI109475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Walker K. J., Walker R. F., Turkes A., Robertson J. F., Blamey R. W., Griffiths K., Nicholson R. I. Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer. Eur J Cancer Clin Oncol. 1989 Apr;25(4):651–654. doi: 10.1016/0277-5379(89)90200-9. [DOI] [PubMed] [Google Scholar]
  25. Welshons W. V., Jordan V. C. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol. 1987 Dec;23(12):1935–1939. doi: 10.1016/0277-5379(87)90062-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES